Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
21
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Salas Eduardo Rene | Director | 14 | $0 | $0 | 2025-04-02 |
| Durgam Suresh K. | SVP, Chief Medical Officer | 92 | $0 | $10.05M | 2025-04-02 |
| Narula Sanjeev | Executive Vice President & CFO | 6 | $0 | $0 | 2025-04-02 |
| Neumann Mark | EVP, Chief Commercial Officer | 120 | $0 | $20.59M | 2025-04-02 |
| Mates Sharon | Chairman, President & CEO | 248 | $0 | $83.58M | 2025-04-02 |
| Halstead Michael | SVP and General Counsel | 178 | $307.6K | $33.40M | 2025-04-02 |
| VAN NOSTRAND ROBERT L | Director | 85 | $5.0K | $5.32M | 2025-04-02 |
| MARCUS JOEL S | Director | 100 | $0 | $13.07M | 2025-04-02 |
| RIGGS RORY B | Director | 89 | $1.01M | $13.96M | 2025-04-02 |
| Hineline Lawrence J. | VP of Finance CFO | 201 | $0 | $35.79M | 2024-03-11 |
| Rawlins Michael | Director | 3 | $0 | $0 | 2022-06-09 |
| LERNER RICHARD A | Director | 70 | $13.7K | $177.4K | 2021-09-30 |
| Alafi Christopher D | Director, 10% Owner | 68 | $35.98M | $3.02M | 2021-05-28 |
| Satlin Andrew | EVP and Chief Medical Officer | 8 | $0 | $302.7K | 2020-02-18 |
| Vanover Kimberly E. | VP, Clinical Development | 39 | $0 | $360.7K | 2019-01-08 |
| Davis Robert E | SVP, Chief Scientific Officer | 27 | $0 | $202.6K | 2019-01-08 |
| ALAFI CAPITAL CO LLC | 10% Owner | 12 | $6.34M | $0 | 2017-10-02 |
| ALAFI MOSHE | 10% Owner | 13 | $6.34M | $100.0K | 2017-10-02 |
| Fienberg Allen A. | VP of Business Development | 11 | $0 | $404.1K | 2015-09-09 |
| Wennogle Lawrence P. | Vice President, Drug Discovery | 23 | $0 | $1.36M | 2015-06-08 |
| Sanchez Juan F. | VP, Corp. Communications & IR | 2 | $0 | $0 | 2015-01-02 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Narula Sanjeev | Executive Vice President & C | D To issuer deriv | 2025-04-02 | 2025-04-02 | 22,727 | — | $0 | 0 | SEC↗ |
| Narula Sanjeev | Executive Vice President & C | D To issuer deriv | 2025-04-02 | 2025-04-02 | 35,046 | — | $0 | 0 | SEC↗ |
| Narula Sanjeev | Executive Vice President & C | D To issuer deriv | 2025-04-02 | 2025-04-02 | 17,251 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 53,967 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | A Award deriv | 2025-04-02 | 2025-04-02 | 8,742 | — | $0 | 8,742 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 8,742 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 18,714 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 17,916 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 13,133 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 17,485 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 24,621 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | A Award deriv | 2025-04-02 | 2025-04-02 | 13,134 | — | $0 | 13,134 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 13,134 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer deriv | 2025-04-02 | 2025-04-02 | 33,443 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 69,940 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 34,970 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 135,399 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 138,473 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 66,886 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 53,471 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 50,167 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 40,713 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 86,003 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 121,212 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | A Award deriv | 2025-04-02 | 2025-04-02 | 40,712 | — | $0 | 40,712 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer deriv | 2025-04-02 | 2025-04-02 | 40,712 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | A Award deriv | 2025-04-02 | 2025-04-02 | 34,970 | — | $0 | 34,970 | SEC↗ |
| MARCUS JOEL S | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 4,322 | — | $0 | 0 | SEC↗ |
| MARCUS JOEL S | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 2,951 | — | $0 | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | D To issuer deriv | 2025-04-02 | 2025-04-02 | 13,133 | — | $0 | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | D To issuer deriv | 2025-04-02 | 2025-04-02 | 17,916 | — | $0 | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | D To issuer deriv | 2025-04-02 | 2025-04-02 | 8,742 | — | $0 | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | A Award deriv | 2025-04-02 | 2025-04-02 | 8,742 | — | $0 | 8,742 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | D To issuer deriv | 2025-04-02 | 2025-04-02 | 13,134 | — | $0 | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | A Award deriv | 2025-04-02 | 2025-04-02 | 13,134 | — | $0 | 13,134 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | D To issuer deriv | 2025-04-02 | 2025-04-02 | 22,727 | — | $0 | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | D To issuer deriv | 2025-04-02 | 2025-04-02 | 17,485 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 4,322 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 7,009 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 2,951 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 16,757 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | A Award deriv | 2025-04-02 | 2025-04-02 | 13,134 | — | $0 | 13,134 | SEC↗ |
| Halstead Michael | President | D To issuer deriv | 2025-04-02 | 2025-04-02 | 40,472 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | D To issuer deriv | 2025-04-02 | 2025-04-02 | 17,916 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | D To issuer deriv | 2025-04-02 | 2025-04-02 | 13,133 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | D To issuer deriv | 2025-04-02 | 2025-04-02 | 12,240 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | A Award deriv | 2025-04-02 | 2025-04-02 | 12,240 | — | $0 | 12,240 | SEC↗ |
| Halstead Michael | President | D To issuer deriv | 2025-04-02 | 2025-04-02 | 13,134 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | D To issuer deriv | 2025-04-02 | 2025-04-02 | 45,454 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | D To issuer deriv | 2025-04-02 | 2025-04-02 | 24,478 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 2,951 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 16,757 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 4,322 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 7,009 | — | $0 | 0 | SEC↗ |
| Salas Eduardo Rene | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 7,009 | — | $0 | 0 | SEC↗ |
| Salas Eduardo Rene | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 2,951 | — | $0 | 0 | SEC↗ |
| Salas Eduardo Rene | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 4,322 | — | $0 | 0 | SEC↗ |
| Salas Eduardo Rene | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 20,000 | — | $0 | 0 | SEC↗ |
| Salas Eduardo Rene | Director | D To issuer deriv | 2025-04-02 | 2025-04-02 | 16,757 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | D To issuer | 2025-04-02 | 2025-04-02 | 42,913 | $132.00 | $5.66M | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer | 2025-04-02 | 2025-04-02 | 945,235 | $132.00 | $124.77M | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | D To issuer | 2025-04-02 | 2025-04-02 | 190,000 | $132.00 | $25.08M | 0 | SEC↗ |
| MARCUS JOEL S | Director | D To issuer | 2025-04-02 | 2025-04-02 | 48,238 | $132.00 | $6.37M | 0 | SEC↗ |
| MARCUS JOEL S | Director | D To issuer | 2025-04-02 | 2025-04-02 | 10,000 | $132.00 | $1.32M | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | D To issuer | 2025-04-02 | 2025-04-02 | 52,811 | $132.00 | $6.97M | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | D To issuer | 2025-04-02 | 2025-04-02 | 11,340 | $132.00 | $1.50M | 0 | SEC↗ |
| Halstead Michael | President | D To issuer | 2025-04-02 | 2025-04-02 | 21,307 | $132.00 | $2.81M | 0 | SEC↗ |
| RIGGS RORY B | Director | D To issuer | 2025-04-02 | 2025-04-02 | 131,512 | $132.00 | $17.36M | 0 | SEC↗ |
| Salas Eduardo Rene | Director | D To issuer | 2025-04-02 | 2025-04-02 | 1,567 | $132.00 | $206.8K | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | G Gift | 2025-03-26 | 2025-03-31 | 190,000 | — | $0 | 190,000 | SEC↗ |
| Mates Sharon | Chairman and CEO | G Gift | 2025-03-26 | 2025-03-31 | 190,000 | — | $0 | 945,235 | SEC↗ |
| Halstead Michael | President | M Exercise deriv | 2025-03-10 | 2025-03-10 | 7,345 | — | $0 | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise deriv | 2025-03-10 | 2025-03-10 | 7,345 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2025-03-10 | 2025-03-10 | 20,566 | — | $0 | 0 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise deriv | 2025-03-10 | 2025-03-10 | 7,345 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | F Tax w/h | 2025-03-10 | 2025-03-10 | 3,757 | $131.24 | $493.1K | 21,307 | SEC↗ |
| Halstead Michael | President | M Exercise | 2025-03-10 | 2025-03-10 | 7,345 | — | $0 | 25,064 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise | 2025-03-10 | 2025-03-10 | 7,345 | — | $0 | 55,927 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | F Tax w/h | 2025-03-10 | 2025-03-10 | 3,116 | $131.24 | $408.9K | 52,811 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2025-03-10 | 2025-03-10 | 20,566 | — | $0 | 1,145,364 | SEC↗ |
| Mates Sharon | Chairman and CEO | F Tax w/h | 2025-03-10 | 2025-03-10 | 10,129 | $131.24 | $1.33M | 1,135,235 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise | 2025-03-10 | 2025-03-10 | 7,345 | — | $0 | 46,029 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | F Tax w/h | 2025-03-10 | 2025-03-10 | 3,116 | $131.24 | $408.9K | 42,913 | SEC↗ |
| Halstead Michael | President | M Exercise deriv | 2025-03-06 | 2025-03-10 | 13,133 | — | $0 | 13,133 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise deriv | 2025-03-06 | 2025-03-10 | 13,133 | — | $0 | 13,133 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2025-03-06 | 2025-03-10 | 40,712 | — | $0 | 40,713 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise deriv | 2025-03-06 | 2025-03-10 | 13,133 | — | $0 | 13,133 | SEC↗ |
| Halstead Michael | President | M Exercise | 2025-03-06 | 2025-03-10 | 13,133 | — | $0 | 24,437 | SEC↗ |
| Halstead Michael | President | F Tax w/h | 2025-03-06 | 2025-03-10 | 6,718 | $131.19 | $881.3K | 17,719 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise | 2025-03-06 | 2025-03-10 | 13,133 | — | $0 | 54,154 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | F Tax w/h | 2025-03-06 | 2025-03-10 | 5,572 | $131.19 | $731.0K | 48,582 | SEC↗ |
| Mates Sharon | Chairman and CEO | F Tax w/h | 2025-03-06 | 2025-03-10 | 19,848 | $131.19 | $2.60M | 1,124,798 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2025-03-06 | 2025-03-10 | 40,712 | — | $0 | 1,144,646 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise | 2025-03-06 | 2025-03-10 | 13,133 | — | $0 | 44,256 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | F Tax w/h | 2025-03-06 | 2025-03-10 | 5,572 | $131.19 | $731.0K | 38,684 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise deriv | 2025-03-01 | 2025-03-04 | 8,742 | — | $0 | 17,485 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise deriv | 2025-03-01 | 2025-03-04 | 8,742 | — | $0 | 17,485 | SEC↗ |
| Halstead Michael | President | M Exercise deriv | 2025-03-01 | 2025-03-04 | 12,239 | — | $0 | 24,478 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2025-03-01 | 2025-03-04 | 34,969 | — | $0 | 69,940 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise | 2025-03-01 | 2025-03-04 | 8,742 | — | $0 | 34,832 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | F Tax w/h | 2025-03-01 | 2025-03-04 | 3,709 | $128.20 | $475.5K | 31,123 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | F Tax w/h | 2025-03-01 | 2025-03-04 | 3,709 | $128.20 | $475.5K | 41,021 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise | 2025-03-01 | 2025-03-04 | 8,742 | — | $0 | 44,730 | SEC↗ |
| Halstead Michael | President | F Tax w/h | 2025-03-01 | 2025-03-04 | 6,261 | $128.20 | $802.7K | 11,304 | SEC↗ |
| Halstead Michael | President | M Exercise | 2025-03-01 | 2025-03-04 | 12,239 | — | $0 | 17,565 | SEC↗ |
| Mates Sharon | Chairman and CEO | F Tax w/h | 2025-03-01 | 2025-03-04 | 16,978 | $128.20 | $2.18M | 1,103,934 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2025-03-01 | 2025-03-04 | 34,969 | — | $0 | 1,120,912 | SEC↗ |
| MARCUS JOEL S | Director | M Exercise deriv | 2025-02-24 | 2025-02-26 | 7,009 | — | $0 | 0 | SEC↗ |
| MARCUS JOEL S | Director | M Exercise | 2025-02-24 | 2025-02-26 | 7,009 | $63.79 | $447.1K | 48,238 | SEC↗ |
| Narula Sanjeev | Executive Vice President & C | A Award deriv | 2025-02-03 | 2025-02-04 | 22,727 | — | $0 | 22,727 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | A Award deriv | 2025-02-03 | 2025-02-04 | 24,621 | — | $0 | 24,621 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | A Award deriv | 2025-02-03 | 2025-02-04 | 22,727 | — | $0 | 22,727 | SEC↗ |
| Halstead Michael | President | A Award deriv | 2025-02-03 | 2025-02-04 | 45,454 | — | $0 | 45,454 | SEC↗ |
| Mates Sharon | Chairman and CEO | A Award deriv | 2025-02-03 | 2025-02-04 | 121,212 | — | $0 | 121,212 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | F Tax w/h | 2025-01-31 | 2025-02-04 | 4,730 | $127.00 | $600.7K | 26,090 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | A Award | 2025-01-31 | 2025-02-04 | 11,017 | — | $0 | 30,820 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | F Tax w/h | 2025-01-31 | 2025-02-04 | 4,729 | $127.00 | $600.6K | 35,988 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | A Award | 2025-01-31 | 2025-02-04 | 11,017 | — | $0 | 40,717 | SEC↗ |
| Halstead Michael | President | A Award | 2025-01-31 | 2025-02-04 | 11,017 | — | $0 | 11,017 | SEC↗ |
| Halstead Michael | President | F Tax w/h | 2025-01-31 | 2025-02-04 | 5,691 | $127.00 | $722.8K | 5,326 | SEC↗ |
| Mates Sharon | Chairman and CEO | A Award | 2025-01-31 | 2025-02-04 | 30,847 | — | $0 | 1,101,176 | SEC↗ |
| Mates Sharon | Chairman and CEO | F Tax w/h | 2025-01-31 | 2025-02-04 | 15,233 | $127.00 | $1.93M | 1,085,943 | SEC↗ |
| RIGGS RORY B | Director | A Award | 2024-12-31 | 2025-01-03 | 215 | $83.52 | $18.0K | 131,512 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-12-05 | 2024-12-06 | 51,697 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-12-05 | 2024-12-06 | 1,534 | $84.69 | $129.9K | 1,070,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-12-05 | 2024-12-06 | 50,163 | $84.06 | $4.22M | 1,071,863 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-12-05 | 2024-12-06 | 51,697 | $12.73 | $658.1K | 1,122,026 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-12-04 | 2024-12-06 | 51,000 | — | $0 | 51,697 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-12-04 | 2024-12-06 | 51,000 | $12.73 | $649.2K | 1,121,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-12-04 | 2024-12-06 | 27,667 | $85.62 | $2.37M | 1,093,662 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-12-04 | 2024-12-06 | 23,333 | $86.00 | $2.01M | 1,070,329 | SEC↗ |
| Halstead Michael | President | M Exercise deriv | 2024-11-13 | 2024-11-14 | 18,714 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | S Sale | 2024-11-13 | 2024-11-14 | 13,371 | $88.17 | $1.18M | 5,343 | SEC↗ |
| Halstead Michael | President | M Exercise | 2024-11-13 | 2024-11-14 | 18,714 | $36.89 | $690.4K | 18,714 | SEC↗ |
| Halstead Michael | President | S Sale | 2024-11-13 | 2024-11-14 | 5,343 | $88.92 | $475.1K | 0 | SEC↗ |
| Halstead Michael | President | M Exercise deriv | 2024-11-12 | 2024-11-14 | 22,869 | — | $0 | 0 | SEC↗ |
| Halstead Michael | President | S Sale | 2024-11-12 | 2024-11-14 | 6,116 | $89.63 | $548.2K | 1,648 | SEC↗ |
| Halstead Michael | President | M Exercise | 2024-11-12 | 2024-11-14 | 22,869 | $23.94 | $547.5K | 22,869 | SEC↗ |
| Halstead Michael | President | S Sale | 2024-11-12 | 2024-11-14 | 1,648 | $90.89 | $149.8K | 0 | SEC↗ |
| Halstead Michael | President | S Sale | 2024-11-12 | 2024-11-14 | 15,105 | $88.72 | $1.34M | 7,764 | SEC↗ |
| RIGGS RORY B | Director | A Award | 2024-09-30 | 2024-10-02 | 246 | $73.17 | $18.0K | 117,108 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-08-30 | 2024-08-30 | 34,396 | — | $0 | 102,697 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-08-30 | 2024-08-30 | 34,396 | $12.73 | $437.9K | 1,104,725 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-30 | 2024-08-30 | 28,203 | $72.73 | $2.05M | 1,076,522 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-30 | 2024-08-30 | 6,193 | $73.32 | $454.1K | 1,070,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-08-29 | 2024-08-30 | 35,604 | — | $0 | 137,093 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-08-29 | 2024-08-30 | 35,604 | $12.73 | $453.2K | 1,105,933 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-29 | 2024-08-30 | 29,832 | $72.44 | $2.16M | 1,076,101 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-29 | 2024-08-30 | 5,772 | $73.25 | $422.8K | 1,070,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-08-28 | 2024-08-28 | 32,699 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-28 | 2024-08-28 | 240 | $73.70 | $17.7K | 1,070,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-28 | 2024-08-28 | 32,459 | $72.74 | $2.36M | 1,070,569 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-08-28 | 2024-08-28 | 32,699 | $17.57 | $574.5K | 1,103,028 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-08-27 | 2024-08-28 | 40,513 | — | $0 | 32,699 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-27 | 2024-08-28 | 16,856 | $73.93 | $1.25M | 1,070,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-27 | 2024-08-28 | 23,657 | $73.33 | $1.73M | 1,087,185 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-08-27 | 2024-08-28 | 40,513 | $17.57 | $711.8K | 1,110,842 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-08-26 | 2024-08-28 | 22,713 | — | $0 | 73,212 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-08-26 | 2024-08-28 | 22,713 | $17.57 | $399.1K | 1,093,042 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-26 | 2024-08-28 | 22,713 | $74.59 | $1.69M | 1,070,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-08-23 | 2024-08-23 | 28,680 | — | $0 | 95,925 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-08-23 | 2024-08-23 | 28,680 | $17.57 | $503.9K | 1,099,009 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-23 | 2024-08-23 | 28,680 | $74.46 | $2.14M | 1,070,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-08-22 | 2024-08-23 | 39,380 | — | $0 | 124,605 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-08-22 | 2024-08-23 | 39,380 | $17.57 | $691.9K | 1,109,709 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-22 | 2024-08-23 | 35,011 | $74.58 | $2.61M | 1,074,698 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-22 | 2024-08-23 | 4,369 | $75.47 | $329.7K | 1,070,329 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-08-21 | 2024-08-23 | 53,013 | — | $0 | 163,985 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-21 | 2024-08-23 | 4,297 | $76.20 | $327.4K | 1,074,911 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-08-21 | 2024-08-23 | 53,013 | $17.57 | $931.4K | 1,123,342 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-21 | 2024-08-23 | 44,134 | $75.40 | $3.33M | 1,079,208 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-21 | 2024-08-23 | 2,682 | $77.21 | $207.1K | 1,072,229 | SEC↗ |
| Mates Sharon | Chairman and CEO | S Sale | 2024-08-21 | 2024-08-23 | 1,900 | $77.98 | $148.2K | 1,070,329 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise deriv | 2024-08-16 | 2024-08-20 | 18,714 | — | $0 | 0 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-08-16 | 2024-08-20 | 18,714 | $75.08 | $1.41M | 29,700 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise | 2024-08-16 | 2024-08-20 | 18,714 | $36.89 | $690.4K | 48,414 | SEC↗ |
| Narula Sanjeev | Executive Vice President & C | A Award deriv | 2024-08-12 | 2024-08-14 | 17,251 | — | $0 | 17,251 | SEC↗ |
| Narula Sanjeev | Executive Vice President & C | A Award deriv | 2024-08-12 | 2024-08-14 | 35,046 | — | $0 | 35,046 | SEC↗ |
| RIGGS RORY B | Director | A Award | 2024-06-28 | 2024-07-02 | 262 | $68.49 | $17.9K | 116,862 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | A Award | 2024-06-28 | 2024-07-02 | 83 | $68.49 | $5.7K | 11,340 | SEC↗ |
| RIGGS RORY B | Director | M Exercise deriv | 2024-06-24 | 2024-06-25 | 20,000 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | S Sale | 2024-06-24 | 2024-06-25 | 4,462 | $75.57 | $337.2K | 116,600 | SEC↗ |
| RIGGS RORY B | Director | M Exercise | 2024-06-24 | 2024-06-25 | 20,000 | $16.86 | $337.2K | 121,062 | SEC↗ |
| RIGGS RORY B | Director | M Exercise deriv | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 0 | SEC↗ |
| MARCUS JOEL S | Director | M Exercise deriv | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 0 | SEC↗ |
| Salas Eduardo Rene | Director | M Exercise deriv | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | M Exercise deriv | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | M Exercise | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 101,062 | SEC↗ |
| MARCUS JOEL S | Director | M Exercise | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 41,229 | SEC↗ |
| Salas Eduardo Rene | Director | M Exercise | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 1,567 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | M Exercise | 2024-06-23 | 2024-06-25 | 1,567 | — | $0 | 11,257 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | M Exercise deriv | 2024-06-18 | 2024-06-21 | 20,000 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | S Sale | 2024-06-18 | 2024-06-21 | 8,891 | $75.71 | $673.1K | 20,799 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | S Sale | 2024-06-18 | 2024-06-21 | 11,109 | $76.07 | $845.1K | 9,690 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | M Exercise | 2024-06-18 | 2024-06-21 | 20,000 | $16.86 | $337.2K | 29,690 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 4,322 | — | $0 | 4,322 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 2,951 | — | $0 | 2,951 | SEC↗ |
| MARCUS JOEL S | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 4,322 | — | $0 | 4,322 | SEC↗ |
| MARCUS JOEL S | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 2,951 | — | $0 | 2,951 | SEC↗ |
| RIGGS RORY B | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 4,322 | — | $0 | 4,322 | SEC↗ |
| RIGGS RORY B | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 2,951 | — | $0 | 2,951 | SEC↗ |
| Salas Eduardo Rene | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 4,322 | — | $0 | 4,322 | SEC↗ |
| Salas Eduardo Rene | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 2,951 | — | $0 | 2,951 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-04-24 | 2024-04-25 | 8,638 | — | $0 | 0 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise deriv | 2024-04-24 | 2024-04-25 | 11,382 | — | $0 | 216,998 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-04-24 | 2024-04-25 | 8,638 | $16.86 | $145.6K | 1,058,947 | SEC↗ |
| Mates Sharon | Chairman and CEO | M Exercise | 2024-04-24 | 2024-04-25 | 11,382 | $17.57 | $200.0K | 1,070,329 | SEC↗ |
| RIGGS RORY B | Director | A Award | 2024-03-31 | 2024-04-02 | 260 | $69.20 | $18.0K | 99,495 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | A Award | 2024-03-31 | 2024-04-02 | 79 | $69.20 | $5.5K | 9,690 | SEC↗ |
| RIGGS RORY B | Director | M Exercise deriv | 2024-03-20 | 2024-03-22 | 20,000 | — | $0 | 0 | SEC↗ |
| RIGGS RORY B | Director | M Exercise | 2024-03-20 | 2024-03-22 | 20,000 | $18.56 | $371.2K | 99,235 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | S Sale | 2024-03-11 | 2024-03-11 | 661 | $66.96 | $44.3K | 19,803 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | S Sale | 2024-03-11 | 2024-03-11 | 2,179 | $65.06 | $141.8K | 21,336 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | S Sale | 2024-03-11 | 2024-03-11 | 872 | $65.89 | $57.5K | 20,464 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-03-11 | 2024-03-11 | 1,313 | $66.86 | $87.8K | 29,700 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-03-11 | 2024-03-11 | 1,729 | $65.92 | $114.0K | 31,013 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-03-11 | 2024-03-11 | 4,303 | $65.11 | $280.2K | 32,742 | SEC↗ |
| Halstead Michael | EVP and General Counsel | S Sale | 2024-03-11 | 2024-03-11 | 1,238 | $66.70 | $82.6K | 0 | SEC↗ |
| Halstead Michael | EVP and General Counsel | S Sale | 2024-03-11 | 2024-03-11 | 6,107 | $65.82 | $402.0K | 1,238 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-03-11 | 2024-03-11 | 1,100 | $66.54 | $73.2K | 29 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-03-11 | 2024-03-11 | 4,475 | $66.47 | $297.5K | 64 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-03-11 | 2024-03-11 | 29 | $67.32 | $2.0K | 0 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-03-11 | 2024-03-11 | 64 | $67.12 | $4.3K | 0 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-03-11 | 2024-03-11 | 4,453 | $65.28 | $290.7K | 1,129 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-03-11 | 2024-03-11 | 1,590 | $66.81 | $106.2K | 1,050,615 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-03-11 | 2024-03-11 | 4,128 | $65.90 | $272.0K | 1,052,205 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-03-11 | 2024-03-11 | 14,541 | $64.80 | $942.3K | 1,056,333 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-03-11 | 2024-03-11 | 306 | $67.33 | $20.6K | 1,050,309 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise deriv | 2024-03-10 | 2024-03-11 | 7,345 | — | $0 | 7,345 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise deriv | 2024-03-10 | 2024-03-11 | 7,345 | — | $0 | 7,345 | SEC↗ |
| Halstead Michael | EVP and General Counsel | M Exercise deriv | 2024-03-10 | 2024-03-11 | 7,345 | — | $0 | 7,345 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | M Exercise deriv | 2024-03-10 | 2024-03-11 | 4,539 | — | $0 | 4,539 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | M Exercise deriv | 2024-03-10 | 2024-03-11 | 5,582 | — | $0 | 5,582 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | M Exercise deriv | 2024-03-10 | 2024-03-11 | 20,565 | — | $0 | 20,566 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise | 2024-03-10 | 2024-03-11 | 7,345 | — | $0 | 23,515 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise | 2024-03-10 | 2024-03-11 | 7,345 | — | $0 | 37,045 | SEC↗ |
| Halstead Michael | EVP and General Counsel | M Exercise | 2024-03-10 | 2024-03-11 | 7,345 | — | $0 | 7,345 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | M Exercise | 2024-03-10 | 2024-03-11 | 4,539 | $56.73 | $257.5K | 4,539 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | M Exercise | 2024-03-10 | 2024-03-11 | 5,582 | — | $0 | 5,582 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | M Exercise | 2024-03-10 | 2024-03-11 | 20,565 | — | $0 | 1,070,874 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | S Sale | 2024-03-07 | 2024-03-11 | 2,722 | $66.86 | $182.0K | 16,170 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | S Sale | 2024-03-07 | 2024-03-11 | 3,728 | $66.34 | $247.3K | 18,892 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-03-07 | 2024-03-11 | 4,496 | $66.95 | $301.0K | 29,700 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-03-07 | 2024-03-11 | 8,636 | $66.37 | $573.2K | 34,196 | SEC↗ |
| Halstead Michael | EVP and General Counsel | S Sale | 2024-03-07 | 2024-03-11 | 220 | $66.81 | $14.7K | 0 | SEC↗ |
| Halstead Michael | EVP and General Counsel | S Sale | 2024-03-07 | 2024-03-11 | 12,912 | $66.14 | $854.0K | 220 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-03-07 | 2024-03-11 | 6,618 | $66.93 | $442.9K | 0 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-03-07 | 2024-03-11 | 6,514 | $66.26 | $431.6K | 6,618 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-03-07 | 2024-03-11 | 31,958 | $66.38 | $2.12M | 1,059,063 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-03-07 | 2024-03-11 | 8,754 | $66.93 | $585.9K | 1,050,309 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise deriv | 2024-03-06 | 2024-03-08 | 13,132 | — | $0 | 26,266 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | M Exercise deriv | 2024-03-06 | 2024-03-08 | 13,132 | — | $0 | 26,266 | SEC↗ |
| Halstead Michael | EVP and General Counsel | M Exercise deriv | 2024-03-06 | 2024-03-08 | 13,132 | — | $0 | 26,266 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | M Exercise deriv | 2024-03-06 | 2024-03-08 | 40,712 | — | $0 | 81,425 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise deriv | 2024-03-06 | 2024-03-08 | 13,132 | — | $0 | 26,266 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | M Exercise | 2024-03-06 | 2024-03-08 | 13,132 | — | $0 | 22,620 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | M Exercise | 2024-03-06 | 2024-03-08 | 13,132 | — | $0 | 13,132 | SEC↗ |
| Halstead Michael | EVP and General Counsel | M Exercise | 2024-03-06 | 2024-03-08 | 13,132 | — | $0 | 13,132 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | M Exercise | 2024-03-06 | 2024-03-08 | 40,712 | — | $0 | 1,091,021 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | M Exercise | 2024-03-06 | 2024-03-08 | 13,132 | — | $0 | 42,832 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | A Award deriv | 2024-03-01 | 2024-03-05 | 104,909 | — | $0 | 104,909 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | A Award deriv | 2024-03-01 | 2024-03-05 | 26,227 | — | $0 | 26,227 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | A Award deriv | 2024-03-01 | 2024-03-05 | 26,227 | — | $0 | 26,227 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | A Award deriv | 2024-03-01 | 2024-03-05 | 26,227 | — | $0 | 26,227 | SEC↗ |
| Halstead Michael | EVP and General Counsel | A Award deriv | 2024-03-01 | 2024-03-05 | 36,717 | — | $0 | 36,717 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | M Exercise deriv | 2024-02-27 | 2024-02-28 | 20,000 | — | $0 | 0 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | S Sale | 2024-02-27 | 2024-02-28 | 10,349 | $73.14 | $756.9K | 9,611 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | S Sale | 2024-02-27 | 2024-02-28 | 9,651 | $72.71 | $701.7K | 19,960 | SEC↗ |
| VAN NOSTRAND ROBERT L | Director | M Exercise | 2024-02-27 | 2024-02-28 | 20,000 | $18.56 | $371.2K | 29,611 | SEC↗ |
| MARCUS JOEL S | Director | M Exercise deriv | 2024-02-26 | 2024-02-27 | 20,000 | — | $0 | 0 | SEC↗ |
| MARCUS JOEL S | Director | M Exercise deriv | 2024-02-26 | 2024-02-27 | 16,757 | — | $0 | 0 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | M Exercise deriv | 2024-02-26 | 2024-02-27 | 5,882 | — | $0 | 0 | SEC↗ |
| MARCUS JOEL S | Director | S Sale | 2024-02-26 | 2024-02-27 | 17,658 | $69.07 | $1.22M | 39,961 | SEC↗ |
| MARCUS JOEL S | Director | S Sale | 2024-02-26 | 2024-02-27 | 8,371 | $67.83 | $567.8K | 57,619 | SEC↗ |
| MARCUS JOEL S | Director | S Sale | 2024-02-26 | 2024-02-27 | 299 | $69.60 | $20.8K | 39,662 | SEC↗ |
| MARCUS JOEL S | Director | M Exercise | 2024-02-26 | 2024-02-27 | 20,000 | $43.45 | $869.0K | 49,233 | SEC↗ |
| MARCUS JOEL S | Director | M Exercise | 2024-02-26 | 2024-02-27 | 16,757 | $55.48 | $929.7K | 65,990 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-02-26 | 2024-02-27 | 1,307 | $71.18 | $93.0K | 29,700 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-02-26 | 2024-02-27 | 2,341 | $70.70 | $165.5K | 31,007 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-02-26 | 2024-02-27 | 4,059 | $69.56 | $282.3K | 33,348 | SEC↗ |
| Neumann Mark | EVP, Chief Commercial Office | S Sale | 2024-02-26 | 2024-02-27 | 200 | $68.03 | $13.6K | 37,407 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | S Sale | 2024-02-26 | 2024-02-27 | 1,312 | $71.02 | $93.2K | 9,488 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | S Sale | 2024-02-26 | 2024-02-27 | 1,400 | $69.38 | $97.1K | 12,200 | SEC↗ |
| Durgam Suresh K. | EVP, Chief Medical Officer | S Sale | 2024-02-26 | 2024-02-27 | 1,400 | $70.16 | $98.2K | 10,800 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-02-26 | 2024-02-27 | 9,528 | $69.45 | $661.7K | 1,062,771 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-02-26 | 2024-02-27 | 12,462 | $70.11 | $873.7K | 1,050,309 | SEC↗ |
| Mates Sharon | Chairman, President & CEO | S Sale | 2024-02-26 | 2024-02-27 | 600 | $68.39 | $41.0K | 1,072,299 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-02-26 | 2024-02-27 | 600 | $69.81 | $41.9K | 0 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-02-26 | 2024-02-27 | 300 | $68.33 | $20.5K | 7,155 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-02-26 | 2024-02-27 | 6,867 | $69.38 | $476.4K | 288 | SEC↗ |
| Hineline Lawrence J. | SVP of Finance, CFO | S Sale | 2024-02-26 | 2024-02-27 | 288 | $70.15 | $20.2K | 0 | SEC↗ |